Compositions and methods for adjuvant cancer therapeutics

A method of treating cancer, comprising administering to a subject in need thereof (i) one or more secondary therapeutic agents and (ii) one or more compounds of formula (I),

• or a pharmaceutically acceptable salt thereof, wherein
• X and Y are independently selected from NR, O, or S,
• where R is hydrogen or C1-C4 alkyl;
• R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, halogen, —NO2, —CN, C1-C6 alkyl, C1-C6 haloalkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, C1-C6 alkoxy, C1-C6 haloalkoxy, —SH, hydroxy(C1-C6 alkyl), alkoxy(C1-C6 alkyl), amino(C1-C6 alkyl), —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, —CO2H, —CO2(C1-C6 alkyl), —CHO, —CO(C1-C6 alkyl), and —S(O)0-2(C1-C6 alkyl);
• R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, —NO2, —CN, C1-C6 alkyl, C1-C6 haloalkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, C1-C6 alkoxy, C1-C6 haloalkoxy, —SH, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, —CO2H, —CO2(C1-C6 alkyl), —CHO, —CO(C1-C6 alkyl), and —S(O)0-2(C1-C6 alkyl),
• or R5 and R6, together with the atoms to which they are attached, form a 5 or 6 membered aryl, heteroaryl, or heterocyclyl;
• R8 is C1-C8 alkyl optionally substituted with one or more R10, C2-C8 alkenyl optionally substituted with one or more R10, or C2-C8 alkynyl optionally substituted with one or more R10,
• wherein each R10 is independently selected from the group consisting of halogen, —NO2, —CN, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, C1-C6 alkoxy, C1-C6 haloalkoxy, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, —CO2H, —CO2(C1-C6 alkyl), —CHO, —CO(C1-C6 alkyl), and —S(O)0-2(C1-C6 alkyl), or two R10 groups when attached to the same carbon atom form ═O, ═NR, or ═N—OH;
• and
• R9 is hydrogen or C1-C4 alkyl.